Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OFATUMUMAB Cause Progressive multifocal leukoencephalopathy? 58 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 58 reports of Progressive multifocal leukoencephalopathy have been filed in association with OFATUMUMAB (ARZERRA). This represents 0.2% of all adverse event reports for OFATUMUMAB.

58
Reports of Progressive multifocal leukoencephalopathy with OFATUMUMAB
0.2%
of all OFATUMUMAB reports
27
Deaths
18
Hospitalizations

How Dangerous Is Progressive multifocal leukoencephalopathy From OFATUMUMAB?

Of the 58 reports, 27 (46.6%) resulted in death, 18 (31.0%) required hospitalization, and 4 (6.9%) were considered life-threatening.

Is Progressive multifocal leukoencephalopathy Listed in the Official Label?

Yes, Progressive multifocal leukoencephalopathy is listed as a known adverse reaction in the official FDA drug label for OFATUMUMAB.

What Other Side Effects Does OFATUMUMAB Cause?

Fatigue (5,202) Headache (4,430) Pain (3,382) Chills (3,372) Pyrexia (3,370) Influenza like illness (2,727) Nausea (1,688) Multiple sclerosis relapse (1,525) Covid-19 (1,435) Asthenia (1,393)

What Other Drugs Cause Progressive multifocal leukoencephalopathy?

NATALIZUMAB (1,668) RITUXIMAB (1,647) CYCLOPHOSPHAMIDE (782) PREDNISONE (606) PREDNISOLONE (439) TACROLIMUS (438) METHOTREXATE (428) DOXORUBICIN (421) MYCOPHENOLATE MOFETIL (414) VINCRISTINE (376)

Which OFATUMUMAB Alternatives Have Lower Progressive multifocal leukoencephalopathy Risk?

OFATUMUMAB vs OFLOXACIN OFATUMUMAB vs OLANZAPINE OFATUMUMAB vs OLANZAPINE\SAMIDORPHAN L-MALATE OFATUMUMAB vs OLAPARIB OFATUMUMAB vs OLARATUMAB

Related Pages

OFATUMUMAB Full Profile All Progressive multifocal leukoencephalopathy Reports All Drugs Causing Progressive multifocal leukoencephalopathy OFATUMUMAB Demographics